Lipella Pharmaceuticals Stock Down 32.91% Since IPO

Lipella Pharmaceuticals LIPO opened up its shares for public trading for the first time since it filed for IPO in July 2022. The company agreed to initially offer 1.22 million shares to the public at $5.75 per share. On its first day of trading, the stock fell 32.91% from its opening price of $7.02 to its closing price of $4.71.

Lipella Pharmaceuticals Performance On First Day of Trading

About Lipella Pharmaceuticals and It's IPO

Lipella Pharmaceuticals Inc is aclinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications.

For its IPO, LIPO agreed to offer 1.22 million shares at a price of $5.75 per share, with an insider lock-up period of 180 days, ending on June 18, 2023.

An insider lock-up period is a period of time after a company first goes public where major shareholders are not allowed to sell their shares. The insider lock-up period makes sure that the market does not get oversupplied with shares of the company.

Traders may short the stock leading up to the lockup-period expiration date in hopes that the price will fall due to an increase in supply of shares. Retail traders should be watching this stock's short interest as it moves closer to lockup expiration.

See also: Benzinga's Most Shorted Stocks

This article was generated by Benzinga's automated content engine and reviewed by an editor.